|
gptkbp:instanceOf
|
antiretroviral therapy
protease inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
2006
|
|
gptkbp:ATCCode
|
J05AE10
|
|
gptkbp:bioavailability
|
37%
|
|
gptkbp:brand
|
gptkb:Prezista
|
|
gptkbp:CASNumber
|
206361-99-1
|
|
gptkbp:category
|
gptkb:WHO_essential_medicine
antiviral drug
HIV/AIDS drug
|
|
gptkbp:chemicalClass
|
sulfonamide
carbamate
secondary alcohol
|
|
gptkbp:contraindication
|
severe liver impairment
|
|
gptkbp:developedBy
|
gptkb:Tibotec
|
|
gptkbp:discoveredBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:rifampin
gptkb:carbamazepine
gptkb:St._John's_wort
phenobarbital
|
|
gptkbp:eliminationHalfLife
|
15 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C27H37N3O7S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
darunavir
|
|
gptkbp:KEGGID
|
D03659
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:mechanismOfAction
|
inhibits HIV-1 protease
|
|
gptkbp:MedlinePlusID
|
a606008
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:oftenCoAdministeredWith
|
gptkb:cobicistat
gptkb:ritonavir
|
|
gptkbp:patentExpired
|
2023 (US)
|
|
gptkbp:pregnancyCategory
|
B (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
213039
DB01264
184856
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
rash
|
|
gptkbp:UNII
|
YO603Y8113
|
|
gptkbp:usedFor
|
HIV infection
|
|
gptkbp:bfsParent
|
gptkb:Prezista
|
|
gptkbp:bfsLayer
|
6
|